> Back to EJC


Previous editions of EJC News Focus

  • November 2011
    Gordon Mills assesses the challenges we face in developing personalised medicine.
  • October 2011
    Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
  • September 2011
    Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
  • August 2011
    Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
  • July 2011
    EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
  • June 2011
    Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
  • April/May 2011
    Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
  • March 2011
    EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
  • February 2011
    Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
  • January 2011
    Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.

EJC News Focus – August 2011

Loading EJC News Focus video


This months’ EJC News Focus explores why researchers need to start using a common language to describe toxicities in phase I trials. The principles underlying early research were devised decades ago to evaluate toxicity associated with chemotherapy. But novel targeted therapies often have quite different side effect profiles, and may be taken for months or years on end.  In order to ensure that the agents most likely to succeed are selected for further research, Jean-Charles Soria, EJC’s Drug Development Editor, says it is time for a new consensus on how to assess toxicities.


See also:
Phase I trials of molecular targeted therapies: Are we evaluating toxicities properly? Jean-Charles Soria, EJC 2011; 47:10 1443-5
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature. Christophe Le Tourneau et al, EJC 2011; 47:10 1468-75